RET and cancer: There were some infrequently reported alterations, including EIF1AX c.338-2A>T splice site KIAA1217-RET fusion, that were considered to be pathogenetic mutations or oncogenic driver genes for malignant tumors, as revealed in previous research (Castagna et al., 2020; Elsherbini et al., 2022; Lee et al., 2016; Song et al., 2022; Davis et al., 2020; Lee et al., 2016).